左西孟旦辅助治疗急性心力衰竭疗效及对NT-proBNP和预后的影响

Curative effect of levosimendan adjuvant therapy on acute heart failure and its influence on NT-proBNP level and prognosis

目的:探讨左西孟旦辅助治疗急性心力衰竭患者疗效及对N末端脑钠肽前体(NT-proBNP)和预后的影响。方法:将80例急性心力衰竭患者根据随机数字表法将其分为对照组和观察组各40例,对照组使用常规基础治疗,观察组在常规治疗基础上增加左西孟旦辅助治疗。比较两组疗效、治疗前后NT-proBNP指标、不良反应率和30 d内主要不良心血管事件发生率。结果:观察组治疗总有效率高于对照组、NT-proBNP和30 d内主要不良心血管事件低于对照组(均P <0.05);两组不良反应比较无统计学意义(P> 0.05)。结论:左西孟旦辅助治疗急性心力衰竭患者疗效较好,能改善NT-proBNP,且安全性较高、预后较好。

Objective:To investigate the effect of levosimendan in the adjuvant treatment of patients with acute heart failure and its influence on N-terminal pro-brain natriuretic peptide(NT-proBNP) level and prognosis.Methods:Eighty patients with acute heart failure were divided into a control group(n=40) and an observation group(n=40) based on a random number table method.The efficacy,NT-proBNP levels before and after treatment,the incidence of adverse reactions and major adverse cardiovascular events within 30 days were compared between the two groups.Results:The overall response rate was higher and the NT-proBNP levels and the incidence of major adverse cardiovascular events in 30 days were lower in the observation group than the control group(all P<0.05).There were no significant differences between the two groups in the incidence of adverse reactions(P>0.05).Conclusion:The adjuvant treatment of levosimendan in patients with acute heart failure is effective,can improve NT-proBNP levels and has higher safety and better prognosis.